AdvanCell Initiates Phase 2 Expansion Trial of ADVC001, a Novel Targeted Alpha Therapy for Prostate Cancer
Clinical development of 212Pb-ADVC001 (ADVC001) is advancing rapidly with encouraging Phase 1b data presented at ESMO 2025 The Phase 2 expansion will evaluate 160 MBq and 200 MBq doses of ADVC001 using a randomized, multi-dose-response design and adaptive dosing strategies to optimize clinical outcomes across three indications: metastatic hormone-sensitive prostate cancer (mHSPC) and metastatic castration-resistant prostate cancer (mCRPC) in pre-chemotherapy and post-177Lu-PSMA radioligand therapy (RLT) settings
AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, today announced the initiation of the TheraPb Phase 2 expansion trial (NCT05720130) evaluating its lead investigational candidate, ADVC001, in metastatic prostate cancer. The news follows the encouraging Phase 1b dose escalation results presented at the European Society for Medical Oncology (ESMO) 2025 congress that showed a favorable safety profile and compelling anti-tumor activity for ADVC001 in patients with mCRPC (see press release).
ADVC001 is a first-in-class 212Pb-PSMA RLT in clinical development, with early data indicating a differentiated and competitive profile both within and beyond its class. Development is advancing rapidly; the Phase 1b therapeutic cohorts were enrolled within ten months, and the commencement of Phase 2 expansion sustains this strong program momentum.
The TheraPb Phase 2 expansion will evaluate ADVC001 at two therapeutic dose levels – 160 MBq and 200 MBq – using a randomized, multi-dose-response design aligned with the US Food and Drug Administration (FDA) guidance on dose optimization for oncology therapeutic radiopharmaceuticals1. The study will incorporate novel dosing strategies and the option for treatment with more than six cycles, supported by the favorable dosimetry and pharmacokinetics data from Phase 1b, to optimize clinical outcomes across three key prostate cancer indications:
- mHSPC: patients with metastatic hormone-sensitive prostate cancer
- mCRPC, pre-chemotherapy: patients with mCRPC who have not received prior chemotherapy for mCRPC
- mCRPC, post-177Lu-PSMA RLT: patients with mCRPC who have been previously treated with 177Lu-PSMA
Enrollment for the TheraPb Phase 2 expansion is expected to commence initially at clinical sites in Australia, with planned expansion to sites in the United States in 2026.
“We are excited to initiate the Phase 2 expansion, marking an important milestone in advancing our novel alpha therapy for prostate cancer,” said Anna Karmann, MD PhD, Chief Medical Officerat AdvanCell. “Our Phase 1 results enable us to evaluate optimal dosing regimens that support a precision treatment strategy aligned with tumor biology and individual response, underscoring our commitment to deliver better clinical outcomes and quality of life for patients living with metastatic prostate cancer.”
“As ADVC001 enters Phase 2, I am eager to begin enrollment in this study,” said Aaron Hansen, MD, Principal Investigator at the Princess Alexandra Hospital. “ADVC001 has demonstrated a highly promising safety and efficacy profile in Phase 1, supporting its investigation in multiple settings. The adaptive dosing and the ability to treat with more than six cycles offer the potential to meaningfully improve clinical benefit and are a step towards more personalized treatment for patients with prostate cancer.”
AdvanCell plans to present additional details on the TheraPb Phase 2 expansion trial design at a major oncology conference in the first half of 2026.
1US Food and Drug Administration (2025, August) “Oncology Therapeutic Radiopharmaceuticals: Dosage Optimization During Clinical Development – Guidance for Industry (Draft Guidance)”
xxx
About 212Pb-ADVC001
212Pb-ADVC001 (ADVC001) is a proprietary and patented PSMA-targeting radioligand with optimized physicochemical properties labelled with 212Pb, an alpha-emitting payload (radionuclide) with a high dose rate, 10.6 hours half-life and simple decay scheme. ADVC001 is designed to deliver radiation at a cellular level to effectively kill prostate cancer cells while minimizing toxicity.
About the TheraPb trial
The TheraPb trial (NCT05720130) is a prospective, open-label Phase 1/2 dose escalation and expansion study designed to determine the safety and tolerability of escalating doses of ADVC001 administered every 6, 4, 2 or 1 week(s) during the dose-finding Phase 1b. The Phase 2 expansion will assess the efficacy and safety of ADVC001 at the recommended Phase 2 doses across three indications. The trial utilizes a randomized dose-response design and dose optimization elements to rigorously evaluate optimal dosing strategies of ADVC001 in PSMA-positive mCRPC and in mHSPC.
About AdvanCell
AdvanCell is a vertically integrated, clinical-stage radiopharmaceutical company dedicated to developing innovative cancer therapies that harness the power of targeted alpha-emitting radionuclides. By leveraging its proprietary 212Pb (Lead-212) platform, advanced and scalable manufacturing and world-class clinical development capabilities, AdvanCell aims to deliver novel treatments that improve outcomes for patients with cancer globally. For more information, visit www.advancell.com.au and follow us on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251202480467/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MUSASHI JAPAN Launches “Gift Campaign 2025” - A Holiday Tradition Honoring Craftsmanship Through Meaningful Gifts2.12.2025 15:07:00 CET | Press release
MUSASHI JAPAN by TAIMATSU announces the return of its year-end celebration, Gift Campaign 2025, a seasonal tradition that transforms holiday shopping into an experience of appreciation, craftsmanship, and cultural generosity. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251202812444/en/ Rather than focusing on discounts, MUSASHI embraces the philosophy that true value lies in tools that last and in the gestures that accompany them. This year’s campaign invites customers to discover gifts that enrich their craft in the kitchen, each thoughtfully chosen to support the longevity and performance of every Musashi blade. Inspired by the Japanese principle of omotenashi, the campaign offers customers tiered gifts based on their total purchase amount, ensuring that every contribution is met with gratitude and purpose. From December 2 to December 25, 2025, customers shopping in MUSASHI JAPAN stores will receive: Tier 1: Oil and Rus
Invisible IT Emerges as Workplace Transformation Evolves, Lenovo Research Finds2.12.2025 15:00:00 CET | Press release
Four out of five IT leaders say their systems can’t keep up and are turning to AI-powered automation to make IT seamless, predictive, and proactive. The next step in workplace transformation is invisible technology that fades into the background so that support is automated and seamless, according to a Lenovo global survey of IT leaders released today. Most employees only notice IT when it slows them down and interrupts processes. Invisible IT is the opposite. It means technology that anticipates needs, prevents issues before they happen, and personalizes support automatically. Achieving Invisible IT, the newest report in Lenovo’s ongoing Work Reborn series, explores how AI and automation are redefining the digital workplace and employee experience. Of the IT leaders who participated, 79% aspire to deliver seamless, proactive support that minimizes disruption for employees, but only 21% have achieved predictive issue resolution. The results underscore an urgent need for organizations t
Wasabi Launches Covert Copy, a Completely Invisible and Indestructible Copy of Data for a Higher Level of Cloud Storage Security2.12.2025 15:00:00 CET | Press release
Key takeaways:A patent pending innovation in data protection that affords the best protection yet from ransomwareEnables account managers to create a hidden, immutable copy of data that is invisible to anyone inside the corporate networkSupports wide range of compliance requirements across all industries Wasabi Technologies, the hot cloud storage company, has expanded its cyber resilient cloud storage capabilities with Covert Copy, a patent pending, advanced ransomware-resistant storage solution that allows users to create a locked, hidden copy of storage buckets to ensure critical data remains untouchable, even in the event of a cyberattack. The selected data is logically air gapped and cannot be seen, accessed, modified or deleted, without multi-user authentication approval, protecting it from any type of malicious attack. Covert Copy strengthens and simplifies traditional air gap strategies by creating a copy of data that is not only isolated, but unable to be detected at all. As th
Incode Launches Deepsight, the World’s Most Accurate Deepfake Defense2.12.2025 15:00:00 CET | Press release
Validated by Purdue University, this breakthrough AI system protects enterprises from deepfakes, synthetic identities, and AI-generated fraud at scale Incode Technologies, the global leader in identity security and fraud prevention, today announced the launch of Deepsight, a breakthrough AI defense that detects and blocks deepfakes, injected virtual cameras, and synthetic identity attacks with unmatched accuracy. When Identity Can Be Faked, Everything Breaks As AI systems increasingly interact and transact autonomously, the ability to instantaneously separate real people from AI-generated fakes becomes critical. Deepsight’s multi-modal AI analyzes video, motion, and depth data to expose inconsistencies that synthetic media cannot reproduce, all in under 100 milliseconds and without adding friction. “Deepfakes have evolved beyond novelty. They are now a major fraud weapon,” said Ricardo Amper, Founder and CEO of Incode. “When identity can be faked, everything breaks. Deepsight restores
Xsolla Advances Global Gaming Education and Innovation in Collaboration With HP2.12.2025 15:00:00 CET | Press release
New Initiative Connects HP’s Gaming Garage and Xsolla’s Accelerator Program to Create a Global Ecosystem for Learning, Development, and Entrepreneurship Xsolla, a leading global video game commerce company that helps developers launch, grow, and monetize their games, today announced a strategic relationship with HP to connect education, technology, and entrepreneurship across the global games industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251202381208/en/ Rytis Joseph Jan, SVP Global Strategic Initiatives & Partnerships at Xsolla The collaboration combines HP’s Gaming Garage learning platform with Xsolla’s Accelerator to create an end-to-end ecosystem that enables aspiring creators to learn, build, and launch their own studios. The integration acts as a catalyst for global opportunities for innovation, introducing new models for game education, incubation, and professional development on a large scale. The program
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom